News　

One of reverSASP Therapeutics’ program, "Development of a novel gene therapy for the treatment of neurodegenerative diseases," has been selected for the Japan Agency for Medical Research and Development (AMED)'s "Strengthening Program for Pharmaceutical Startup Ecosystem" in the fiscal year 2024.

The Strengthening Program for Pharmaceutical Startup Ecosystem is an initiative to "strengthen Japan's drug discovery capabilities through supporting the new drug development and commercialization carried out by pharmaceutical startup companies .https://www.amed.go.jp/koubo/19/02/1902C_00056.html